Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT

v3.19.2
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)
Total
Common Stock Shares
Preferred Stock Shares
Additional Paid-in Capital
Accumulated Deficit
Stockholders Deficit - TransBiotec Inc
Noncontrolling Interest
Beginning Balance, shares at Jan. 01, 2016   67,751,068        
Beginning Balance, Amount at Jan. 01, 2016 $ (3,011,880) $ 677 $ 14,095,430 $ (17,064,086) $ (2,967,979) $ (43,901)
Common stock issued for cash, shares   7,202,679        
Common stock issued for cash, Amount 60,200 $ 72 60,128 60,200
Common stock issued due to options exercise, shares   32,248,932        
Common stock issued due to options exercise, Amount 112,871 $ 323 112,548 112,871
Common stock issued to settle related party payable, shares   2,151,417        
Common stock issued to settle related party payable, Amount 11,516 $ 23 11,493 11,516
Common stock issued to settle non-related party debt, shares   55,834        
Common stock issued to settle non-related party debt, Amount 18,067 $ 1 18,066 18,067
Preferred stock issued for debt, shares   1,388,575        
Preferred stock issued for debt, Amount 14 $ 14 14
Paid-in capital - fair value of stock warrants granted, Amount 19,969 19,969 19,969
Paid-in capital - stock warrants amortization, Amount 86,955 86,955 86,955
Paid-in capital - fair value of stock compensation, Amount 6,290 6,290 6,290
Paid-in capital - gain on related party debt conversion, Amount 182,111 182,111 182,111
Paid-in capital - reclassification of common share equivalents to derivative liabilities, Amount (312,202) (312,202) (312,202)
Paid-in capital - reclassification of derivative liabilities to common share equivalents, Amount 504,263 504,263 504,263
Net loss for the year (642,311) (639,085) (639,085) (3,226)
Ending Balance, shares at Dec. 31, 2017   109,409,930 1,388,575        
Beginning Balance, Amount at Dec. 31, 2017 (2,964,137) $ 1,096 $ 14 14,785,051 (17,703,171) (2,917,010) (47,127)
Common stock issued due to options exercise, shares   450,000        
Common stock issued due to options exercise, Amount 4,500 $ 5 4,495 4,500
Common stock issued to settle related party payable, shares   91,148        
Common stock issued to settle related party payable, Amount 428 $ 1 427 428
Paid-in capital - fair value of stock warrants granted, Amount 29,701 29,701 29,701
Common stock issued for services,shares   6,000,000        
Common stock issued for services, Amount 25,800 $ 61 25,739 25,800
Common stock issued for compensation,shares   800,000        
Common stock issued for compensation, Amount 8,000 $ 9 7,991 8,000
Paid-in capital - gain on related party debt conversion, Amount 28,400 28,400 28,400
Net loss for the year (562,123) (558,965) (558,965) (3,158)
Paid-in capital - beneficial conversion feature 6,000 6,000 6,000
Ending Balance, shares at Dec. 31, 2018   116,751,078 1,388,575        
Beginning Balance, Amount at Dec. 31, 2018 $ (3,423,431) $ 1,172 $ 14 $ 14,887,804 $ (18,262,136) $ (3,373,146) $ (50,285)